Your browser doesn't support javascript.
loading
Assessing thyroid cancer risk using polygenic risk scores.
Liyanarachchi, Sandya; Gudmundsson, Julius; Ferkingstad, Egil; He, Huiling; Jonasson, Jon G; Tragante, Vinicius; Asselbergs, Folkert W; Xu, Li; Kiemeney, Lambertus A; Netea-Maier, Romana T; Mayordomo, Jose I; Plantinga, Theo S; Hjartarson, Hannes; Hrafnkelsson, Jon; Sturgis, Erich M; Brock, Pamela; Nabhan, Fadi; Thorleifsson, Gudmar; Ringel, Matthew D; Stefansson, Kari; de la Chapelle, Albert.
Affiliation
  • Liyanarachchi S; Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210.
  • Gudmundsson J; Department of Cancer Biology and Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210.
  • Ferkingstad E; Department of Population Genomics, deCODE genetics/Amgen Inc., 101 Reykjavik, Iceland.
  • He H; Department of Population Genomics, deCODE genetics/Amgen Inc., 101 Reykjavik, Iceland.
  • Jonasson JG; Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210.
  • Tragante V; Department of Cancer Biology and Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210.
  • Asselbergs FW; Department of Pathology, Landspitali-University Hospital, 101 Reykjavik, Iceland.
  • Xu L; Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland.
  • Kiemeney LA; Department of Epidemiology, The Icelandic Cancer Registry, 105 Reykjavik, Iceland.
  • Netea-Maier RT; Department of Population Genomics, deCODE genetics/Amgen Inc., 101 Reykjavik, Iceland.
  • Mayordomo JI; Department of Cardiology, Heart and Lung Division, University Medical Center Utrecht, University of Utrecht, 3584 CX Utrecht, The Netherlands.
  • Plantinga TS; Department of Cardiology, Heart and Lung Division, University Medical Center Utrecht, University of Utrecht, 3584 CX Utrecht, The Netherlands.
  • Hjartarson H; Durrer Center for Cardiovascular Research, Netherlands Heart Institute, 3511 EP Utrecht, The Netherlands.
  • Hrafnkelsson J; Institute of Cardiovascular Science, Faculty of Population Health Sciences, University College London, WC1E 6BT London, United Kingdom.
  • Sturgis EM; Farr Institute of Health Informatics Research, University College London, NW1 2DA London, United Kingdom.
  • Brock P; Institute of Health Informatics, University College London, NW1 2DA London, United Kingdom.
  • Nabhan F; Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
  • Thorleifsson G; Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
  • Ringel MD; Radboud Institute for Health Sciences, Radboud University Medical Centre, 6500HB Nijmegen, The Netherlands.
  • Stefansson K; Division of Endocrinology, Department of Internal Medicine, Radboud Institute for Health Sciences, Radboud University Medical Centre, 6500HB Nijmegen, The Netherlands.
  • de la Chapelle A; UCHealth Diane O'Connor Thompson Breast Center, University of Colorado Hospital, Aurora, CO 80045.
Proc Natl Acad Sci U S A ; 117(11): 5997-6002, 2020 03 17.
Article in En | MEDLINE | ID: mdl-32132206
ABSTRACT
Genome-wide association studies (GWASs) have identified at least 10 single-nucleotide polymorphisms (SNPs) associated with papillary thyroid cancer (PTC) risk. Most of these SNPs are common variants with small to moderate effect sizes. Here we assessed the combined genetic effects of these variants on PTC risk by using summarized GWAS results to build polygenic risk score (PRS) models in three PTC study groups from Ohio (1,544 patients and 1,593 controls), Iceland (723 patients and 129,556 controls), and the United Kingdom (534 patients and 407,945 controls). A PRS based on the 10 established PTC SNPs showed a stronger predictive power compared with the clinical factors model, with a minimum increase of area under the receiver-operating curve of 5.4 percentage points (P ≤ 1.0 × 10-9). Adding an extended PRS based on 592,475 common variants did not significantly improve the prediction power compared with the 10-SNP model, suggesting that most of the remaining undiscovered genetic risk in thyroid cancer is due to rare, moderate- to high-penetrance variants rather than to common low-penetrance variants. Based on the 10-SNP PRS, individuals in the top decile group of PRSs have a close to sevenfold greater risk (95% CI, 5.4-8.8) compared with the bottom decile group. In conclusion, PRSs based on a small number of common germline variants emphasize the importance of heritable low-penetrance markers in PTC.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Thyroid Neoplasms / Biomarkers, Tumor / Genetic Predisposition to Disease / Multifactorial Inheritance / Thyroid Cancer, Papillary Type of study: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: America do norte / Europa Language: En Year: 2020 Type: Article

Full text: 1 Database: MEDLINE Main subject: Thyroid Neoplasms / Biomarkers, Tumor / Genetic Predisposition to Disease / Multifactorial Inheritance / Thyroid Cancer, Papillary Type of study: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: America do norte / Europa Language: En Year: 2020 Type: Article